158 related articles for article (PubMed ID: 37984228)
1. Obesity is an independent risk factor for cancer development following diagnosis of dermatomyositis.
Allenzara A; Sadeghi N; Alvarez C; Maczuga S; Helm M; Olsen N; Nelson A; Foulke G
Semin Arthritis Rheum; 2024 Feb; 64():152283. PubMed ID: 37984228
[TBL] [Abstract][Full Text] [Related]
2. Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China.
Chen D; Yuan S; Wu X; Li H; Qiu Q; Zhan Z; Ye Y; Lian F; Liang L; Xu H; Yang X
Clin Exp Rheumatol; 2014; 32(5):615-21. PubMed ID: 25068842
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis.
Fardet L; Dupuy A; Gain M; Kettaneh A; Chérin P; Bachelez H; Dubertret L; Lebbe C; Morel P; Rybojad M
Medicine (Baltimore); 2009 Mar; 88(2):91-97. PubMed ID: 19282699
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.
Chow WH; Gridley G; Mellemkjaer L; McLaughlin JK; Olsen JH; Fraumeni JF
Cancer Causes Control; 1995 Jan; 6(1):9-13. PubMed ID: 7718740
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study.
Motomura K; Yamashita H; Yamada S; Takahashi Y; Kaneko H
Rheumatol Int; 2019 Oct; 39(10):1733-1739. PubMed ID: 31444556
[TBL] [Abstract][Full Text] [Related]
6. Risk of Malignancy in Dermatomyositis and Polymyositis.
Qiang JK; Kim WB; Baibergenova A; Alhusayen R
J Cutan Med Surg; 2017; 21(2):131-136. PubMed ID: 27534779
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies.
Shao C; Li S; Sun Y; Zhang Y; Xu K; Zhang X; Huang H
Medicine (Baltimore); 2020 Aug; 99(34):e21899. PubMed ID: 32846853
[TBL] [Abstract][Full Text] [Related]
9. Elevated cancer incidence in patients with dermatomyositis: a population based study.
Airio A; Pukkala E; Isomäki H
J Rheumatol; 1995 Jul; 22(7):1300-3. PubMed ID: 7562762
[TBL] [Abstract][Full Text] [Related]
10. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study.
Yang Z; Lin F; Qin B; Liang Y; Zhong R
J Rheumatol; 2015 Feb; 42(2):282-91. PubMed ID: 25448790
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence of cancer in the Afro-Caribbean population presenting dermatomyositis and anti-synthetase syndrome: a preliminary study conducted at Pointe-à-Pitre University Hospital, 2000-2012].
Tersiguel AC; Longueville C; Beltan E; Vincent T; Tressières B; Cordel N
Ann Dermatol Venereol; 2014 Oct; 141(10):575-80. PubMed ID: 25288059
[TBL] [Abstract][Full Text] [Related]
12. The overall and temporal association of cancer with polymyositis and dermatomyositis.
Zantos D; Zhang Y; Felson D
J Rheumatol; 1994 Oct; 21(10):1855-9. PubMed ID: 7837150
[TBL] [Abstract][Full Text] [Related]
13. Evidence supports blind screening for internal malignancy in dermatomyositis: Data from 2 large US dermatology cohorts.
Leatham H; Schadt C; Chisolm S; Fretwell D; Chung L; Callen JP; Fiorentino D
Medicine (Baltimore); 2018 Jan; 97(2):e9639. PubMed ID: 29480875
[TBL] [Abstract][Full Text] [Related]
14. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
[TBL] [Abstract][Full Text] [Related]
15. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study.
Stockton D; Doherty VR; Brewster DH
Br J Cancer; 2001 Jul; 85(1):41-5. PubMed ID: 11437400
[TBL] [Abstract][Full Text] [Related]
16. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis.
Azuma K; Yamada H; Ohkubo M; Yamasaki Y; Yamasaki M; Mizushima M; Ozaki S
Mod Rheumatol; 2011 Apr; 21(2):178-83. PubMed ID: 20922453
[TBL] [Abstract][Full Text] [Related]
17. Cancer risk in dermatomyositis: a meta-analysis of cohort studies.
Olazagasti JM; Baez PJ; Wetter DA; Ernste FC
Am J Clin Dermatol; 2015 Apr; 16(2):89-98. PubMed ID: 25721032
[TBL] [Abstract][Full Text] [Related]
18. Malignancy in dermatomyositis: A retrospective paired case-control study of 202 patients from Central China.
Chang L; Zhang L; Jia H; Nie Z; Zhang L
Medicine (Baltimore); 2020 Aug; 99(34):e21733. PubMed ID: 32846794
[TBL] [Abstract][Full Text] [Related]
19. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis.
Hoesly PM; Sluzevich JC; Jambusaria-Pahlajani A; Lesser ER; Heckman MG; Abril A
J Am Acad Dermatol; 2019 May; 80(5):1364-1370. PubMed ID: 30458207
[TBL] [Abstract][Full Text] [Related]
20. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
